Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
Gisslinger, Heinz, Buxhofer-Ausch, Veronika, Thaler, Josef, Schlögl, Ernst, Gastl, Gunther, Wolf, Dominik, Schalling, Martin, Gisslinger, Bettina, Ban, Sarita, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Krauth, Maria Theresa, Them, Nicole C.C., Kralovics, Robert, Zörer, Michael, Ammann-Mwathi, Oliver, Kadlecova, Pavla, Zagrijtschuk, Oleh, Klade, Christoph, Greil, Richard
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
Buxhofer-Ausch, Veronika, Gisslinger, Heinz, Thaler, Josef, Schlögl, Ernst, Gastl, Gunther, Wolf, Dominik, Kralovics, Robert, Gisslinger, Bettina, Ban, Sarita, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Schalling, Martin, Krauth, Maria Theresa, Them, Nicole C.C., Zörer, Michael, Ammann-Mwathi, Oliver, Kadlecova, Pavla, Zagrijtschuk, Oleh, Klade, Christoph, Greil, Richard
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article